With an alternative way of producing proteins from plants as a selling point, Biolex Inc. raised $24 million in its latest private round, which it hopes will be its last. (BioWorld Today)

With an alternative way of producing proteins from plants as a selling point, Biolex Inc. raised $24 million in its latest private round, which it hopes will be its last. (BioWorld Today)

Adding to the legal drama between Genzyme General and the remnants of its Biosurgery unit, a class-action lawsuit was initiated on behalf of the division's stockowners through an amendment to the original suit filed by two of its largest. (BioWorld Today)

Adding to the legal drama between Genzyme General and the remnants of its Biosurgery unit, a class-action lawsuit was initiated on behalf of the division's stockowners through an amendment to the original suit filed by two of its largest. (BioWorld Today)

Based on a cross-licensing patent agreement with Genentech Inc. related to humanized antibodies signed nearly five years ago, Protein Design Labs Inc. and company followers were happily eyeing certain Genentech product sales and the potential for more as other products received approval. (BioWorld Today)

Based on a cross-licensing patent agreement with Genentech Inc. related to humanized antibodies signed nearly five years ago, Protein Design Labs Inc. and company followers were happily eyeing certain Genentech product sales and the potential for more as other products received approval. (BioWorld Today)